NCT00979992 2020-02-19Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian CancerNational Cancer Institute (NCI)Phase 2 Completed35 enrolled 9 charts
NCT00768144 2018-08-24Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal CarcinomaDana-Farber Cancer InstitutePhase 2 Completed36 enrolled 10 charts
NCT01824615 2018-07-18Sunitinib® in Patients With Recurrent Ovarian Clear Cell CarcinomaCathay General HospitalPhase 2 Completed30 enrolled
NCT00474994 2016-01-20Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasMemorial Sloan Kettering Cancer CenterPhase 2 Completed53 enrolled 6 charts
NCT00453310 2015-10-27Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to TreatmentMemorial Sloan Kettering Cancer CenterPhase 2 Completed10 enrolled 6 charts